NCT03188419View on ClinicalTrials.gov

Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide

CompletedOBSERVATIONAL
Enrollment

161

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

December 29, 2019

Study Completion Date

February 20, 2020

Conditions
Primary T-cell Immunodeficiency DisordersCommon Variable Immunodeficiency
Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03188419 - Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide | Biotech Hunter | Biotech Hunter